Inovio Pharmaceuticals Inc (Inovio) is a biotechnology company focused on the discovery and development of DNA medicines designed to treat and prevent disease. The company develops DNA-based immunotherapies and vaccines across multiple therapeutic areas, including cancers, HPV-related pre-cancers, and infectious diseases. Inovio’s approach centers on delivering engineered DNA plasmids that are intended to generate targeted immune responses, addressing unmet needs in the healthcare market through innovative, platform-driven therapeutics.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Inovio is focused on developing and commercializing DNA medicines to treat and protect against HPV-associated diseases, cancer, and infectious diseases. The company's lead candidate, INO-3107, is being developed for the treatment of recurrent respiratory papillomatosis (RRP). Other products in the pipeline include INO-3112 for oropharyngeal squamous cell carcinoma and INO-5401 for glioblastoma multiforme and cancers with BRCA1/2 mutations. The company is also working on DNA-Encoded Protein (DPROT) and DNA-Encoded Monoclonal Antibody (DMAb) preclinical stage candidates and technology. The R&D unit of Inovio Pharmaceuticals Inc is responsible for research and development activities, including developing proprietary device technologies, DNA medicine candidates, and dMABs. The unit manages clinical trials, research, and development efforts related to these initiatives. As of December 2025, the company has approximately 45 issued U.S. patents and approximately 40 U.S. patent applications, as well as approximately 500 issued foreign counterpart patents and approximately 355 counterpart foreign patent applications. The company has a pipeline of DNA medicine candidates and major technology alliances with partners such as ApolloBio Corporation, AstraZeneca, Coherus Biosciences, and others. In FY2025, the company spent US$54.2 million on its R&D activities, which declined 28.3% YoY.